Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
c-Met/PD-L1 CAR-T in Primary Hepatocellular Carcinoma
NCT03672305Phase 1Unknown
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of c-Met/PD-L1 CAR-T cell in hepatocellular carcinoma (HCC), sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoints: Objective Tumor Remission Rate at 48 weeks, Overall Survival at 6 months and 2 more. Status: unknown.
02
Drugs
c-Met/PD-L1 CAR-T cell
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03672305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672305.